Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Evinacumab · 1 trial · 1 indication
Change in total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglyceride, non-HDL-Cholesterol and apolipoprotein B plasma concentration
| Arm | Type | Description |
|---|---|---|
| Evinacumab-treated patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Evinacumab | DRUG | Evinacumab 15 mg/kg administered intravenously every 4 weeks |
Inclusion Criteria: * HoFH patients having been previously or being currently treated with evinacumab or clinical diagnosis of HoFH requiring additional lipid lowering therapy. Exclusion Criteria: * Any new condition or worsening of an existing condition, which in the opinion of the investigator ...
Evinacumab is being developed for the treatment of homozygous familial hypercholesterolemia, a rare inherited metabolic condition. It is a monoclonal antibody studied in a Phase 3 clinical trial in adults with this condition. It is an investigational therapy and is not described as approved.
Evinacumab targets ANGPTL3, also known as angiopoietin-like protein 3. It is an inhibitor of ANGPTL3, meaning it acts by blocking the activity of this protein. This mechanism underlies its development for lowering cholesterol in homozygous familial hypercholesterolemia.
Evinacumab is being developed by Ultragenyx Pharmaceutical Inc., which trades under the ticker RARE. The company is the sponsor associated with the clinical development of this monoclonal antibody for homozygous familial hypercholesterolemia.
Evinacumab is in Phase 3 development for homozygous familial hypercholesterolemia. One Phase 3 trial has been completed, and no active trials are currently listed. It is an investigational drug and is not described as FDA approved.
Evinacumab has been studied in the Phase 3 trial NCT05611528, titled Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia. The trial enrolled 10 adults in Canada and is completed. It was an uncontrolled study without randomization or double blinding.